Latest News and Press Releases

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...

Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...

SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...

In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while...

Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...

Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024...